Technology
Health
Pharmaceutical

CytRx

$0.755
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0101 (-1.33%) Today
+$0.005 (0.67%) After Hours

Why Robinhood?

You can buy or sell CytRx and other stocks, options, ETFs, and crypto commission-free!

About

CytRx Corp. operates as a biopharmaceutical research and development company specializing in oncology. It focuses on discovering, developing, and commercializing new therapeutics to treat patients with cancer; including aldoxorubicin, a modified version of the widely-used chemotherapeutic agent, doxorubicin. Read More The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.

Employees
20
Headquarters
Los Angeles, California
Founded
1985
Market Cap
25.57M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
200.09K
High Today
$0.7789
Low Today
$0.73
Open Price
$0.7789
Volume
122.27K
52 Week High
$2.05
52 Week Low
$0.33

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Research And Development
Therapy
Cancer Prevention
US

News

Yahoo FinanceMar 12

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

Novel Imaging Agent Would Enable Oncologists to Predict Which Patients Will Respond to Albumin-Binding Cytotoxic Treatment LOS ANGELES, March 12, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology treatment and diagnostics, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for its Albumin Companion Diagnostic (ACDx). The article, titled "Dev...

298
PR NewswireMar 5

Biotech Companies Intensify Research Into New Therapies to Combat Cancer

NEW YORK, March 5, 2019 /PRNewswire/ -- Cancer ranks among one of the top causes of death globally and data show that the number is still expected to increase.

796
MarketBeatMar 4

NASDAQ:CYTR - Stock Price, News, & Analysis for CytRx

CytRx Corporation, a biopharmaceutical company, engages in the research and clinical development of novel anti-cancer drug candidates that employ linker technologies to enhance the accumulation and release of drug at the tumor.

138

Earnings

-$0.19
-$0.15
-$0.11
-$0.07
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.07 per share
Actual
Expected Mar 28, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.